Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Abstract
Objective null Two similarly designed, phase-3 studies (VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD [VIEW 1, VIEW 2]) of neovascular age-related macular degeneration (AMD) compared monthly and every-2-month dosing of intravitreal aflibercept injection (VEGF Trap-Eye; Regeneron, Tarrytown, NY, and Bayer HealthCare, Berlin, Germany) with monthly ranibizumab. null Design null Double-masked, multicenter, parallel-group,...
Paper Details
Title
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Published Date
Dec 1, 2012
Journal
Volume
119
Issue
12
Pages
2537 - 2548
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History